IRIS BIOTECHNOLOGIES INC - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - November 13, 2012

Attached files
FileFilename
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR20.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR6.htm
10-Q - FORM 10-Q - IRIS BIOTECHNOLOGIES INCirsb11082012form10q.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR27.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR10.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR5.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR26.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR21.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR34.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR16.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR14.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR13.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR15.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR19.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR23.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR11.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR4.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR18.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR1.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR17.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR3.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR7.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR24.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR22.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR2.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR32.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR8.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR31.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR30.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR28.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR29.htm
EXCEL - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR9.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR25.htm
XML - IDEA: XBRL DOCUMENT - IRIS BIOTECHNOLOGIES INCR33.htm
EX-32 - EXHIBIT 32.1 - IRIS BIOTECHNOLOGIES INCirsb11132012exh321.htm
EX-31 - EXHIBIT 31.1 - IRIS BIOTECHNOLOGIES INCirsb11132012exh311.htm
v2.4.0.6
WARRANTS AND OPTIONS
 3 Months Ended
Sep. 30, 2012
Other Liabilities Disclosure [Abstract]  
WARRANTS AND OPTIONS

NOTE 5 – WARRANTS AND OPTIONS

  

Warrants

 

The following table summarizes the changes in warrants outstanding and related prices for the shares of the Company’s common stock issued to shareholders at September 30, 2012:

 

Exercise

Price

    

Number

Outstanding

    

Warrants Outstanding

Weighted Average

Remaining Contractual

Life (years)

    

Weighted

Average

Exercise price

    

Number

Exercisable

    

Warrants Exercisable

Weighted

Average

Exercise Price

  
$ 0.13       40,000       1.72     $ 0.13       40,000     $ 0.13  
  2.25       23,629       0.31       2.25       23,629       2.25  
          63,629                       63,629          

 

Transactions involving the Company’s warrant issuance are summarized as follows:

 

   

Number of

Shares

    

Weighted

Average

Price Per Share

  
        Outstanding at December 31, 2010     95,029     $ 1.29  
        Issued     —       —  
        Exercised     —       —  
        Expired     (17,500 )     (2.00 )
        Outstanding at December 31, 2011     77,529     $ 1.11  
        Issued     —       —  
        Exercised     —       —  
        Expired     (13,900 )     (2.00 )
        Outstanding at September 30, 2012     63,629     $ 0.92  

 

 Options

 

Employee Options

 

The following table summarizes the changes in options outstanding and the related prices for the shares of the Company’s common stock issued to employees under a stock option plan at September 30, 2012:

 

      Options Outstanding     Options Exercisable  

Exercise

Prices (S)

    

Number

Outstanding

    

Weighted Average

Remaining

Contractual Life

(Years)

    

Weighted

Average

Exercise

Price (S)

    

Number

Exercisable

    

Weighted

Average

Exercise

Price

  
$ 0.13       80,000       6.72     $ 0.13       80,000     $ 0.13  
  0.15       400,000       1.72       0.15       400,000       0.15  
  0.80       85,000       8.45       0.80       31,875       0.80  
  1.00       846,875       4.02       1.00       761,875       1.00  
  1.11       200,000       8.25       1.11       83,333       1.11  
  2.25       167,696       5.65       2.25       167,696       2.25  
          1,779,571              $ 0.89       1,524,779      $ 0.87  

 

 

13

 

Transactions involving employee stock options issued are summarized as follows:

 

    Number of Shares    

Weighted Average

Price Per Share

  
        Outstanding at December 31, 2010:     1,481,571     $ 0.86  
        Granted     285,000       1.02  
        Exercised     —       —  
        Canceled or expired     (72,000 )     (0.86 )
        Outstanding at December 31, 2011     1,694,571     $ 0.88  
        Granted     85,000       1.00  
        Exercised     —       —  
        Expired     —       —  
        Outstanding at September 30, 2012:     1,779,571     $ 0.89  

 

On July 11, 2012, the Company granted 85,000 employee stock options with an exercise price of $1.00 vesting over four years and expiring ten years from issuance. The fair value (as determined as described below) of $33,358 is charged ratably over the vesting term of the options.

 

The fair value of these stock options granted and the significant assumptions used to determine those fair values, using a Black-Scholes option-pricing model are as follows:

 

Significant assumptions:      
        Risk-free interest rate at grant date     1.54 %
        Expected stock price volatility     157.05 %
        Expected dividend payout     —  
        Expected option life-years (a)     10  

__________________________

(a)The expected option life is based on contractual expiration dates

 

The fair values of issued vesting options were $19,714 and $94,732 for the three and nine months ended September 30, 2012, respectively; and $41,439 and $115,597 for the three and nine months ended September 30, 2011, respectively.

 

Non-employee options

 

The following table summarizes the changes in options outstanding and the related prices for the shares of the Company’s common stock issued to non-employees under a stock option plan at September 30, 2012:

    

      Options Outstanding     Options Exercisable  

Exercise

Prices

    

Number

Outstanding

    

Weighted Average

Remaining

Contractual Life

(Years)

    

Weighted

Average

Exercise

Price

    

Number

Exercisable

    

Weighted

Average

Exercise

Price

  
 $ 1.00       110,000       3.45      $ 1.00       110,000      $ 1.00  
  1.40       105,000       6.48       1.40       105,000       1.40  
          215,000              $ 1.20       215,000      $ 1.20  

 

Transactions involving non-employee stock options issued are summarized as follows:

 

 

 

14

 

    Number of Shares    

Weighted Average

Price Per Share

  
       Outstanding at December 31, 2010:     375,000     $ 0.90  
       Granted     —       —  
       Exercised     —       —  
       Expired     (120,000 )     (0.50 )
       Outstanding at December 31, 2011     255,000     $ 1.09  
       Granted     —       —  
       Exercised     —       —  
       Expired     (40,000 )      (0.50 )
       Outstanding at September 30, 2012:     215,000     $ 1.20  

 

The fair value of the vested portion of previously granted non-employee options of $Nil and $6,672 was charged during the three and nine months ended September 30, 2012, respectively; and $6,848 and $22,605 for the three and nine months ended September 30, 2011, respectively.

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA


This web site and associated pages are not associated with, endorsed by, or sponsored by IRIS BIOTECHNOLOGIES INC and has no official or unofficial affiliation with IRIS BIOTECHNOLOGIES INC


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.